Sign In
to Vote &
Create Storyboards.
 
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has announced the publication of a peer-reviewed paper demonstrating the success of its new DNA plasmid technology in generating therapeutic monoclonal antibodies. In this study in mice, a prototype monoclonal antibody construct encoding for an established anti-HIV monoclonal antibody (VRC01) was created as a DNA plasmid using Inovio's patented DNA optimization technologACy, including codon/RNA optimization and leader sequence utilization, and deliver...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard